Treatment Adherence to Nucleos(t)ide Analogs in Chinese Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Single-Center Cross-Sectional Study

References

• Chen WQ, Sun KX, Zheng RS, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018;30(1):1–12. doi:10.21147/j.issn.1000-9604.2018.01.01
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16:453–463. doi:10.1111/j.1365-2893.2009.01117.x
   PubMed Web of Science ®Google Scholar
• Herbst DA, Reddy KR. Risk factors for hepatocellular carcinoma. Clin Liver Dis. 2012;1:180–182. doi:10.1002/cld.111
   Google Scholar
• El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273. doi:10.1053/j.gastro.2011.12.061
   PubMed Web of Science ®Google Scholar
• Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123–135. doi:10.1038/nrc3449
   PubMed Web of Science ®Google Scholar
• Hilleret MN, Larrat S, Stanke-Labesque F, Leroy V. Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough? J Hepatol. 2011;55:1468–1469. doi:10.1016/j.jhep.2011.04.006
   Web of Science ®Google Scholar
• Sogni P, Carrieri MP, Fontaine H, et al. The role of adherence in virological suppression in patients receiving anti-HBV analogues. Antivir Ther. 2012;17:395–400. doi:10.3851/IMP1944
   Web of Science ®Google Scholar
• Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, Lok AS. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs (VBT). J Viral Hepat. 2012;19:205–212. doi:10.1111/j.1365-2893.2011.01494.x
   PubMed Web of Science ®Google Scholar
• Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology. 2010;139:1207–1217. doi:10.1053/j.gastro.2010.06.053
   PubMed Web of Science ®Google Scholar
• Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol. 2011;54:12–18. doi:10.1016/j.jhep.2010.06.016
   PubMed Web of Science ®Google Scholar
• Manolakopoulos S, Striki A, Papastergiou V, et al. Persistence and adherence to nucleos(t)ide analogues in chronic hepatitis B: a multicenter cohort study. Eur J Gastroenterol Hepatol. 2020;32(5):635–641. doi:10.1097/MEG.0000000000001558
   Web of Science ®Google Scholar
• Peng J, Yin JH, Cai SH. Factors associated with adherence to nucleos(t)ide analogs in chronic hepatitis B patients: results from a 1-year follow-up study. Patient Prefer Adherence. 2015;9:41–45. doi:10.2147/PPA.S71510
   PubMed Web of Science ®Google Scholar
• van Vlerken LG, Arends P, Lieveld FI, et al. Real life adherence of chronic hepatitis B patients to entecavir treatment. Digest Liver Dis. 2015;47:577–583. doi:10.1016/j.dld.2015.03.024
   Web of Science ®Google Scholar
• Giang L, Selinger CP, Lee AU. Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires. World J Hepatol. 2012;4:43–49. doi:10.4254/wjh.v4.i2.43
   PubMedGoogle Scholar
• Hirai K, Shiozaki M, Motooka H, et al. Discrimination between worry and anxiety among cancer patients: development of a brief cancer-related worry inventory. Psychooncology. 2008;17:1172–1179. doi:10.1002/pon.1348
   PubMed Web of Science ®Google Scholar
• Mackenzie LJ, Carey ML, Sanson-Fisher RW, D’Este CA, Paul CL, Yoong SL. Agreement between HADS classifications and single-item screening questions for anxiety and depression: a cross-sectional survey of cancer patients. Ann Oncol. 2014;25:889–895. doi:10.1093/annonc/mdu023
   Web of Science ®Google Scholar
• Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale: an updated literature review. J Pyschosom Res. 2002;52:69–77. doi:10.1016/S0022-3999(01)00296-3
   PubMed Web of Science ®Google Scholar
• Pericot-Valverde I, Rennert L, Heo M, et al. Rates of perfect self-reported adherence to direct-acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: the PREVAIL study. J Viral Hepat. 2021;28(3):548–557. doi:10.1111/jvh.13445
   Web of Science ®Google Scholar
• Zhang Q, Li X, Qiao S, Shen Z, Zhou Y. Comparing self-reported medication adherence measures with hair antiretroviral concentration among people living with HIV in Guangxi, China. AIDS Res Ther. 2020;17(1):8. doi:10.1186/s12981-020-00265-4
   PubMed Web of Science ®Google Scholar
• Burton MJ, Voluse AC, Patel AB, Konkle-Parker D. Measuring adherence to hepatitis C direct-acting antiviral medications: using the VAS in an HCV treatment clinic. South Med J. 2018;111(1):45–50. doi:10.14423/SMJ.0000000000000750
   Web of Science ®Google Scholar
• Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160:31–37.
   PubMed Web of Science ®Google Scholar
• Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol. 2002;18:649–656.
   PubMed Web of Science ®Google Scholar
• Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalaminein quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929–2933. doi:10.1111/j.1572-0241.2001.04683.x
   PubMed Web of Science ®Google Scholar
• Anand BS, Currie S, Dieperink E, et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology. 2006;130:1607–1616. doi:10.1053/j.gastro.2006.02.023
   PubMed Web of Science ®Google Scholar
• Ha NB, Ha NB, Garcia RT, et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci. 2011;56:2423–2431. doi:10.1007/s10620-011-1610-5
   Web of Science ®Google Scholar
• Kamezaki H, Kanda T, Arai M, et al. Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with ETV than in those with lamivudine. Int J Med Sci. 2013;10:567–574. doi:10.7150/ijms.5795
   PubMed Web of Science ®Google Scholar